| dc.rights.license | open | en_US |
| dc.contributor.author | TESTAERT, Hugo | |
| hal.structure.identifier | Université de Bordeaux [UB] | |
| dc.contributor.author | BOUET, Margaux | |
| hal.structure.identifier | Lyon Bone and Joint Infection Study Group [BJI] | |
| dc.contributor.author | VALOUR, Florent | |
| dc.contributor.author | GIGANDON, Anne | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | LAFON, Marie-Edith | |
| hal.structure.identifier | Croix-Rousse Hospital, Hospices civils de Lyon | |
| dc.contributor.author | PHILIT, François | |
| hal.structure.identifier | hôpital Louis-Pradel, CHU de Lyon, 69500 Bron, France. | |
| dc.contributor.author | SÉNÉCHAL, Agathe | |
| hal.structure.identifier | Institut des Agents Infectieux [Lyon] [IAI] | |
| hal.structure.identifier | Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] [CNR - laboratoire associé] | |
| hal.structure.identifier | Virology and human respiratory Pathologies - Virology and human respiratory Pathologies [CIRI] [VirPath] | |
| dc.contributor.author | CASALEGNO, Jean-Sébastien | |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | BLANCHARD, Elodie | |
| hal.structure.identifier | Centre Chirurgical Marie Lannelongue [CCML] | |
| hal.structure.identifier | Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT] | |
| dc.contributor.author | LE PAVEC, Jérôme | |
| hal.structure.identifier | Hospices Civils de Lyon [HCL] | |
| hal.structure.identifier | Centre International de Recherche en Infectiologie [CIRI] | |
| dc.contributor.author | ADER, Florence | |
| dc.date.accessioned | 2024-09-02T13:16:47Z | |
| dc.date.available | 2024-09-02T13:16:47Z | |
| dc.date.issued | 2021-06 | |
| dc.identifier.issn | 1198-743X | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/201374 | |
| dc.description.abstractEn | Objectives: To analyse functional outcome parameters according to antimicrobial treatments after respiratory syncytial virus (RSV)-confirmed infection in adult lung transplant recipients.
Methods: A 9-year retrospective multicentre cohort study (2011-19) included adult lung transplant recipients with RSV-confirmed infection. The first endpoint determined new allograft dysfunction (acute graft rejection and chronic lung allograft dysfunction (CLAD)) 3 months after infection. Then baseline and 3 months' postinfection forced expiratory volume in 1 second (FEV1) values were compared according to antimicrobial treatment. Univariate logistic regression analysis was performed.
Results: RSV infection was confirmed in 77 of 424 lung transplant recipients (estimated incidence of 0.025 per patient per year; 95% confidence interval 0.018-0.036). At 3 months, 22 recipients (28.8%) developed allograft dysfunction: ten (13%) possible CLAD, six (7.9%) acute rejection and six (7.9%) CLAD. Recipients with the lowest preinfection FEV1 had a greater risk of developing pneumonia (median (interquartile range) 1.5 (1.1-1.9) vs. 2.2 (1.5-2.4) L/s, p 0.003) and a higher odds of receiving antibiotics (1.6 (1.3-2.3) vs. 2.3 (1.9-2.5) L/s, p 0.017; odds ratio 0.52, 95% confidence interval 0.27-0.99). Compared to tracheobronchitis/bronchiolitis, RSV-induced pneumonia led more frequently to hospitalization (91.7%, 22 vs. 58.0%, 29, p 0.003) and intensive care unit admission (33.3%, 8 vs. 0, p < 10-3). For ribavirin-treated recipients (24.7%, 19) and azithromycin prophylaxis (50.6%, 39), 3-month FEV1 values were not different from untreated recipients. The overall mortality was 2.5% at 1 month and 5.3% at 6 months, unrelated to RSV.
Conclusions: At 3 months after RSV-confirmed infection, 22 recipients (28.8%) had new allograft dysfunction. Ribavirin treatment and azithromycin prophylaxis did not prevent FEV1 decline. | |
| dc.language.iso | EN | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/ | |
| dc.subject.en | Azithromycin; Bronchiolitis obliterans syndrome; Chronic lung allograft dysfunction; Graft rejection; Lung transplantation; Respiratory syncytial virus; Ribavirin. | |
| dc.title.en | Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study | |
| dc.title.alternative | Clin Microbiol Infect | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.cmi.2020.07.050 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio] | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Microbiologie et Parasitologie | en_US |
| dc.identifier.pubmed | 32827713 | en_US |
| bordeaux.journal | Clinical Microbiology and Infection | en_US |
| bordeaux.page | 897-903 | en_US |
| bordeaux.volume | 27 | en_US |
| bordeaux.hal.laboratories | MFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234 | en_US |
| bordeaux.issue | 6 | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | hal | |
| hal.identifier | hal-04532474 | |
| hal.version | 1 | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | false | |
| workflow.import.source | hal | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Microbiology%20and%20Infection&rft.date=2021-06&rft.volume=27&rft.issue=6&rft.spage=897-903&rft.epage=897-903&rft.eissn=1198-743X&rft.issn=1198-743X&rft.au=TESTAERT,%20Hugo&BOUET,%20Margaux&VALOUR,%20Florent&GIGANDON,%20Anne&LAFON,%20Marie-Edith&rft.genre=article | |
